Beam Therapeutics

YTD

ALL

Trade Beam Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BEAM

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201.

CEO

John Evans

CEOJohn Evans

Employees

483

Employees483

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2017

Founded2017

Employees

483

Employees483

BEAM Key Statistics

Market cap

1.71B

Market cap1.71B

Price-Earnings ratio

-3.74

Price-Earnings ratio-3.74

Dividend yield

—

Dividend yield—

Average volume

2.26M

Average volume2.26M

High today

$17.64

High today$17.64

Low today

$16.80

Low today$16.80

Open price

$17.00

Open price$17.00

Volume

1.74M

Volume1.74M

52 Week high

$35.25

52 Week high$35.25

52 Week low

$13.53

52 Week low$13.53

Analyst ratings

88%

of 16 ratings

Buy

87.5%

Hold

12.5%

Sell

People also own

Based on the portfolios of people who own BEAM. This list is generated using Robinhood data, and it’s not a recommendation.

CRISPR

Intellia Therapeutics

Editas Medicine

Recursion Pharmaceuticals

Archer Aviation

IonQ